

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark. Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexendria, Virginia 22313-1450 www.mpio.gov

DATE MAILED: 03/23/2004

FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. FILING DATE APPLICATION NO. P2730P1C6 4963 11/14/2001 Avi J. Ashkenazi 09/992,521 EXAMINER 35489 7590 HELLER EHRMAN WHITE & MCAULIFFE LLP KAUFMAN, CLAIRE M 275 MIDDLEFIELD ROAD ART UNIT PAPER NUMBER MENLO PARK, CO 94025-3506

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/992,521	ASHKENAZI ET AL.
Office Action Summary	Examiner	Art Unit
	Claire M. Kaufman	1646
The MAILING DATE of this communication eriod for Reply	n appears on the cover sheet wi	th the correspondence address
A SHORTENED STATUTORY PERIOD FOR R THE MAILING DATE OF THIS COMMUNICAT! Extensions of time may be available under the provisions of 37 c after SIX (6) MONTHS from the mailing date of this communication I the period for reply sepecified above, the maximum statutory. I MO period for reply is specified above, the maximum statutory Failure to reply within the set or extended period for reply will. by Any reply received by the Office later than three months after the earned patent turn adjustment. See 37 CFR 1.7061.	ION. FR 1.136(a). In no event, however, may a re on, a reply within the statutory minimum of thirt period will apply and will expire SIX (6) MON statute, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on	14 November 2001.	
2a) ☐ This action is FINAL. 2b) ☑	This action is non-final.	
3) Since this application is in condition for al	llowance except for formal matt	ers, prosecution as to the merits is
closed in accordance with the practice un	ider <i>Ex parte Quayle</i> , 1935 C.D	. 11, 453 O.G. 213.
Disposition of Claims		
4) ⊠ Claim(s) 119-124 is/are pending in the ap  4a) Of the above claim(s) is/are wit  5) □ Claim(s) is/are allowed.  6) ⊠ Claim(s) 119-124 is/are rejected.  7) ☑ Claim(s) is/are objected to.  8) □ Claim(s) are subject to restriction as	thdrawn from consideration.	
Application Papers		
9) The specification is objected to by the Exa 10) The drawing(s) filed on 14 November 200 Applicant may not request that any objection Replacement drawing sheet(s) including the c 11) The oath or declaration is objected to by t	01 is/are: a)  accepted or b) to the drawing(s) be held in abeyar correction is required if the drawing	nce. See 37 CFR 1.85(a). (s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of:  1. Certified copies of the priority docu 2. Certified copies of the priority docu 3. Copies of the certified copies of the application from the International E * See the attached detailed Office action for	uments have been received. uments have been received in A e priority documents have been Bureau (PCT Rule 17.2(a)).	Application No received in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)		Summary (PTO-413) s)/Mail Date
<ol> <li>Notice of Draftsperson's Patent Drawing Review (PTO-94)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/92)</li> <li>Paper No(s)/Mail Date 5/28/02.</li> </ol>	SB/08) 5) Notice of I	syman Date Informal Patent Application (PTO-152) Informal Patent Application (PTO-152) Information (PTO-152)

Application/Control Number: 09/992,521

Art Unit: 1646

#### DETAILED ACTION

### Claim Rejections - 35 USC § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 119 and 124 and dependent claims 120-123 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 119 and 124 are indefinite because claim 119 recites "binds" and claim 124 recites "specifically binds". Absent a definition of "specific binding", it is not clear what the difference between the two claims is and what each claim is meant to encompass, given that antibody binding is determined by the variable regions structure and is a "specific" event.

## Priority

Priority application 09/380,137 and earlier filed priority applications do *not* meet the requirements of 35 U.S.C. § 112, first paragraph. Because there was no function associated with PRO1282 and the skilled artisan would not have known how to use it, the prior application also does not meet those requirements and, therefore, is unavailable under 35 U.S.C. § 120. Note that even if priority were granted to the earliest filed priority application 60/097,979, the art rejection below would remain under 35 UCS 102(e).

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language. Application/Control Number: 09/992,521

Art Unit: 1646

Claims 119-130 are rejected under 35 U.S.C. 102(e) as being anticipated by US 6,225,085.

US 6,225,085 teaches a LRSG (leucine-rich surface glycoprotein) of SEQ ID NO:2 which is identical to SEQ ID NO:52 of the instant application (see attached SEQUENCE COMPARISON). Also disclosed are anti-LRSG antibodies and well known methods of making them, including monoclonal (e.g. col. 22, lines 62-63, and col. 23, line 37, through col. 24, line 32), chimeric, humanized (col. 24, lines 33-56), labeled (col. 25, lines2-17) antibodies and antibody fragments (col. 22, lines 59-62).

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire M. Kaufman, whose telephone number is (571)272-0873. Dr. Kaufman can generally be reached Monday, Tuesday and Thursday from 8:30AM to 2:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached at (571)272-0871.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Official papers filed by fax should be directed to (703) 872-9306. NOTE: If applicant does submit a paper by fax, the original signed copy should be retained by the applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Claire M. Kaufman, Ph.D.

Patent Examiner, Art Unit 1646

March 17, 2004

# SEQUENCE COMPARISON OF SEQ ID NO:52 WITH US 6,225,085

```
; Sequence 2, Application US/09063950C
; Patent No. 6225085
 GENERAL INFORMATION:
  APPLICANT: Holtzman, Douglas A.
  TITLE OF INVENTION: NOVEL LRSG PROTEIN AND NUCLEIC ACID MOLECULES AND USES
 TITLE OF INVENTION: THEREFOR
 CURRENT APPLICATION NUMBER: US/09/063,950C
 CURRENT FILING DATE: 1998-04-21
SEQ ID NO 2
   LENGTH: 673
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-063-950-2
                    100.0%; Score 3520; DB 3; Length 673;
 Query Match
                          Pred. No. 5.8e-249;
 Best Local Similarity 100.0%;
                                       0: Indels
                                                     Gaps
                                                           0;
 Matches 673; Conservative
                         0; Mismatches
         1 MCSRVPLLLPLLLLLALGPGVQGCPSGCQCSQPQTVFCTARQGTTVPRDVPPDTVGLYVF 60
Qv
           1 MCSRVPLLLPLLLLALGPGVQGCPSGCQCSQPQTVFCTARQGTTVPRDVPPDTVGLYVF 60
Db
        61 ENGITMLDAGSFAGLPGLQLLDLSQNQIASLPSGVFQPLANLSNLDLTANRLHEITNETF 120
Qv
           61 ENGITMLDAGSFAGLPGLQLLDLSQNQIASLPSGVFQPLANLSNLDLTANRLHEITNETF 120
Db
       121 RGLRRLERLYLGKNRIRHIQPGAFDTLDRLLELKLQDNELRALPPLRLPRLLLLDLSHNS 180
Qy
           121 RGLRRLERLYLGKNRIRHIQPGAFDTLDRLLELKLQDNELRALPPLRLPRLLLLDLSHNS 180
Db
        181 LLALEPGILDTANVEALRLAGLGLQQLDEGLFSRLRNLHDLDVSDNQLERVPPVIRGLRG 240
           181 LLALEPGILDTANVEALRLAGLGLQQLDEGLFSRLRNLHDLDVSDNQLERVPPVIRGLRG 240
Db
       241 LTRLRLAGNTRIAQLRPEDLAGLAALQELDVSNLSLQALPGDLSGLFPRLRLLAAARNPF 300
           241 LTRLRLAGNTRIAQLRPEDLAGLAALQELDVSNLSLQALPGDLSGLFPRLRLLAAARNPF 300
Db
        301 NCVCPLSWFGPWVRESHVTLASPEETRCHFPPKNAGRLLLELDYADFGCPATTTTATVPT 360
Qy
           301 NCVCPLSWFGPWVRESHVTLASPEETRCHFPPKNAGRLLLELDYADFGCPATTTTATVPT 360
Db
        361 TRPVVREPTALSSSLAPTWLSPTAPATEAPSPPSTAPPTVGPVPQPQDCPPSTCLNGGTC 420
Qу
           361 TRPVVREPTALSSSLAPTWLSPTAPATEAPSPPSTAPPTVGPVPQPQDCPPSTCLNGGTC 420
Db
        421 HLGTRHHLACLCPEGFTGLYCESQMGQGTRPSPTPVTPRPPRSLTLGIEPVSPTSLRVGL 480
Qv
           421 HLGTRHHLACLCPEGFTGLYCESQMGQGTRPSPTPVTPRPPRSLTLGIEPVSPTSLRVGL 480
Db
        481 ORYLOGSSVQLRSLRLTYRNLSGPDKRLVTLRLPASLAEYTVTQLRPNATYSVCVMPLGP 540
           481 QRYLQGSSVQLRSLRLTYRNLSGPDKRLVTLRLPASLAEYTVTQLRPNATYSVCVMPLGP 540
Db
```

QУ		GRVPEGEEACGEAHTPPAVHSNHAPVTQAREGNLPLLIAPALAAVLLAALAAVGAAYCVR	
Db		GRVPEGEEACGEAHTPPAVHSNHAPVTQAREGNLPLLIAPALAAVLLAALAAVGAAYCVR	
Qy		RGRAMAAAAQDKGQVGPGAGPLELEGVKVPLEPGPKATEGGGEALPSGSECEVPLMGFPG	
Db	601	${\tt RGRAMAAAAQDKGQVGPGAGPLELEGVKVPLEPGPKATEGGGEALPSGSECEVPLMGFPG}$	660
Qу	661	PGLQSPLHAKPYI 673	
Db	661	PGLQSPLHAKPYI 673	